Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone

Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone

Giant cell tumor of bone (GCTB) is a rare bone tumor often necessitating surgical intervention, radiation therapy, or treatment with bisphosphonates or denosumab. 99mTc-MDP bone scintigraphy for GCTB has limited specificity, and the relatively high uptake of 18F-FDG in GCTB makes it challenging to d...

Full description

Saved in:

Bibliographic Details
Main Authors:	Brenna C. McAllister, Nooshin Mesbahi, Esther E. Dodson, Sakinah Abdulsalam, Clifford E. Berkman, Leslie A. Caromile
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Oncology
Subjects:	prostate specific membrane antigen (PSMA) repurposable drugs Pluvicto Locametz giant cell tumor of bone (GCTB)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1504514/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A comparison of routine [68Ga]Ga-PSMA-11 preparation using Locametz and Illuccix kits
by: Ivan E. Wang, et al.
Published: (2024-12-01)

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)

Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry
by: Pete Tually, et al.
Published: (2024-12-01)

Incidental discovery of gastrointestinal stromal tumor via PSMA-PET/CT imaging: Insights from a case report
by: Venetia A. Florou, et al.
Published: (2025-01-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer
by: Marco M. E. Vogel, et al.
Published: (2025-01-01)

Genomic strategies for drug repurposing
by: Kirtan Dave, et al.
Published: (2024-11-01)

Imply on diagnosis and early prognosis of preoperative [68Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin
by: K. Pełka, et al.
Published: (2025-01-01)

Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform
by: Sebastian Martin, et al.
Published: (2024-12-01)

Investigating the significance of SPECT/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review
by: Tahani O. Alkahtani
Published: (2025-01-01)

Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01)

Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice
by: Antonio Ivanov, et al.
Published: (2024-12-01)

Gastric Adenocarcinoma Incidentally Detected by PET/CT with PSMA Ligands
by: Cesare Michele Iacovitti, et al.
Published: (2025-01-01)

Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report
by: Yu-Yi Huang, et al.
Published: (2025-01-01)

Research progress in drug repurposing in the treatment of breast cancer
by: TAN Chen, et al.
Published: (2024-11-01)

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)

Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [18F]PSMA-1007 PET/CT: a comparison to MRI using histopathology as reference
by: Erland Hvittfeldt, et al.
Published: (2025-01-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Current State of Evidence and Practice of Prostate-Specific Membrane Antigen (Psma) Imaging Across the Prostate Cancer Clinical Landscape – Oncologist Perspective
by: Antonela Njavro, et al.
Published: (2024-01-01)

The Domestic Reuse and Repurposing of Packaging: The Materiality of Sustainable Practices
by: Tenno Teidearu
Published: (2024-01-01)

High-throughput tracking enables systematic phenotyping and drug repurposing in C. elegans disease models
by: Thomas J O'Brien, et al.
Published: (2025-01-01)

cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer
by: Gary Amseian, et al.
Published: (2024-12-01)

PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny
by: Mohammad A. Alzubi, et al.
Published: (2025-02-01)

Radiation-induced morphea of the breast – characterization and treatment of fibroblast dysfunction with repurposed mesalazine
by: Stephan R. Künzel, et al.
Published: (2024-10-01)

Preoperative detection of extraprostatic tumor extension in patients with primary prostate cancer utilizing [68Ga]Ga-PSMA-11 PET/MRI
by: Clemens P. Spielvogel, et al.
Published: (2024-12-01)

Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms
by: She Pengfei, et al.
Published: (2024-12-01)

IUPHAR review: Drug repurposing in Schizophrenia – An updated review of clinical trials
by: Jihan K. Zaki, et al.
Published: (2025-03-01)

Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma
by: Ilham Badrane, et al.
Published: (2024-12-01)

Partial volume correction for Lu-177-PSMA SPECT
by: Yibin Liu, et al.
Published: (2024-11-01)

Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy
by: Benjamin Challis, et al.
Published: (2025-01-01)

Comprehensive evaluation of pure and hybrid collaborative filtering in drug repurposing
by: Clémence Réda, et al.
Published: (2025-01-01)

Evaluating [<sup>68</sup>Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study
by: Andrea Di Giorgio, et al.
Published: (2024-12-01)

Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
by: Chawalit Ngernsombat, et al.
Published: (2024-12-01)

Effectiveness of drug repurposing approach against Candida isolates
by: Ayesha Ansari, et al.
Published: (2024-09-01)

Drug repurposing in the treatment of chronic inflammatory diseases
by: Shivmuni Sarup, et al.
Published: (2024-11-01)

Repurposed drugs as histone deacetylase 8 inhibitors: Implications in cancer and neuropathological conditions
by: Mohammed Alrouji, et al.
Published: (2024-11-01)

Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study
by: Junjie Fan, et al.
Published: (2025-02-01)

Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma
by: Vijay M. Patil, et al.
Published: (2020-07-01)

Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose in 177LuPSMA therapy of metastatic castration-resistant prostate cancer (mCRPC) using Monte Carlo simulation
by: Sirwan Maroufpour, et al.
Published: (2024-12-01)

Recent advances in antileishmanial drugs: New leishmaniasis medicine through repurposing approach
by: Lon-Fye Lye, et al.
Published: (2024-09-01)